Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
BACKGROUND Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but… Expand
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Through the adoptive transfer of lymphocytes after host immunodepletion, it is possible to mediate objective cancer regression in human patients with metastatic melanoma. However, the generation of… Expand
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a… Expand
Cancer immunotherapy: moving beyond current vaccines
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on… Expand
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
- R. Morgan, James C. Yang, M. Kitano, M. Dudley, C. Laurencot, S. Rosenberg
- Molecular therapy : the journal of the American…
- 1 April 2010
In an attempt to treat cancer patients with ERBB2 overexpressing tumors, we developed a chimeric antigen receptor (CAR) based on the widely used humanized monoclonal antibody (mAb) Trastuzumab… Expand
Adoptive cell transfer as personalized immunotherapy for human cancer
Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT using naturally… Expand
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
- James C. Yang, Leah R. Haworth, +6 authors S. Rosenberg
- The New England journal of medicine
- 31 July 2003
BACKGROUND Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab,… Expand
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
- S. Rosenberg, N. Restifo, James C. Yang, R. Morgan, M. Dudley
- Nature Reviews Cancer
- 1 April 2008
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer… Expand
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
We studied the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells plus interleukin-2 or therapy with high-dose interleukin-2 alone in 157 patients with metastatic cancer… Expand
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
- M. Dudley, J. Wunderlich, +18 authors S. Rosenberg
- Journal of clinical oncology : official journal…
- 1 April 2005
PURPOSE We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory… Expand